Prabhjot Singh Mundi

This study identifies non-oncogene dependencies in imatinib-resistant GIST using network-based methods and validates six drugs that reverse MR activity in preclinical models.

The paper identifies ATR as a target for combination EZH2 epigenetic therapy in SMARCB1-deficient sarcomas, showing that EZH2 inhibition promotes DNA damage via PGBD5, and that ATR inhibition enhances therapeutic responses.

The paper identifies six molecular subtypes of GIST using single nucleus RNA sequencing and correlates them with clinicopathologic features and clinical outcomes.

The paper identifies treatment-resistant Cancer Stem-Like Cells in breast cancer using single-cell RNA sequencing and validates a drug combination to target them effectively.

The paper uses large-scale perturbation profiles to analyze drug mechanisms of action and polypharmacology across multiple tumor subtypes and tissues.

The paper validates an RNA-based platform for predicting drug sensitivity in treatment-resistant cancers using patient-derived xenograft models and multi-protein therapies.